HERON THERAPS INC Company Profile
✉ Email this page to a colleague
What is the competitive landscape for HERON THERAPS INC, and when can generic versions of HERON THERAPS INC drugs launch?
HERON THERAPS INC has four approved drugs.
There are thirty-two US patents protecting HERON THERAPS INC drugs.
There are ninety-seven patent family members on HERON THERAPS INC drugs in twenty-one countries and seven supplementary protection certificates in four countries.
Summary for HERON THERAPS INC
| International Patents: | 97 |
| US Patents: | 32 |
| Tradenames: | 4 |
| Ingredients: | 3 |
| NDAs: | 4 |
Drugs and US Patents for HERON THERAPS INC
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Heron Theraps Inc | ZYNRELEF KIT | bupivacaine; meloxicam | SOLUTION, EXTENDED RELEASE;PERIARTICULAR | 211988-002 | May 12, 2021 | RX | Yes | Yes | 9,592,227 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Heron Theraps Inc | SUSTOL | granisetron | INJECTION, EXTENDED RELEASE;SUBCUTANEOUS | 022445-001 | Aug 9, 2016 | RX | Yes | Yes | 10,357,570 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Heron Theraps Inc | CINVANTI | aprepitant | EMULSION;INTRAVENOUS | 209296-001 | Nov 9, 2017 | RX | Yes | Yes | 9,974,742 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Heron Theraps Inc | ZYNRELEF KIT | bupivacaine; meloxicam | SOLUTION, EXTENDED RELEASE;PERIARTICULAR | 211988-004 | May 12, 2021 | RX | Yes | Yes | 11,253,504 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Heron Theraps Inc | CINVANTI | aprepitant | EMULSION;INTRAVENOUS | 209296-001 | Nov 9, 2017 | RX | Yes | Yes | 10,953,018 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Heron Theraps Inc | ZYNRELEF KIT | bupivacaine; meloxicam | SOLUTION, EXTENDED RELEASE;PERIARTICULAR | 211988-002 | May 12, 2021 | RX | Yes | Yes | 11,844,837 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Heron Theraps Inc | ZYNRELEF KIT | bupivacaine; meloxicam | SOLUTION, EXTENDED RELEASE;PERIARTICULAR | 211988-004 | May 12, 2021 | RX | Yes | Yes | 10,980,886 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for HERON THERAPS INC
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Heron Theraps Inc | SUSTOL | granisetron | INJECTION, EXTENDED RELEASE;SUBCUTANEOUS | 022445-001 | Aug 9, 2016 | 6,613,355 | ⤷ Try a Trial |
| Heron Theraps Inc | SUSTOL | granisetron | INJECTION, EXTENDED RELEASE;SUBCUTANEOUS | 022445-001 | Aug 9, 2016 | 6,790,458 | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for HERON THERAPS INC Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 6977003 | ⤷ Try a Trial |
| World Intellectual Property Organization (WIPO) | 2015164272 | ⤷ Try a Trial |
| European Patent Office | 3936115 | ⤷ Try a Trial |
| European Patent Office | 3785700 | ⤷ Try a Trial |
| Denmark | 3134068 | ⤷ Try a Trial |
| Taiwan | I407966 | ⤷ Try a Trial |
| Japan | 2015034182 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for HERON THERAPS INC Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0748320 | 08C0019 | France | ⤷ Try a Trial | PRODUCT NAME: FOSAPREPITANT DIMEGLUMINE; REGISTRATION NO/DATE: EU/1/07/437/001 20080111 |
| 0734381 | 3/2004 | Austria | ⤷ Try a Trial | PRODUCT NAME: APREPITANT, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEMBAREN SALZES; REGISTRATION NO/DATE: EU/1/03/262/001 - EU/1/03/262/006 20031111 |
| 0748320 | SPC/GB08/021 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: FOSAPREPITANT AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, IN PARTICULAR THE BIS(N-METHYL-D-GLUCAMINE)SALT; REGISTERED: UK EU/1/07/437/001 20080111; UK EU/1/07/437/002 20080111 |
| 0734381 | 04C0010 | France | ⤷ Try a Trial | PRODUCT NAME: APREPITANT; REGISTRATION NO/DATE: EU/1/03/262/001 20031111 |
| 0734381 | SPC/GB04/011 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: APREPITANT, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: UK EU/1/03/262/001 20031113; UK EU/1/03/262/002 20031113; UK EU/1/03/262/003 20031113; UK EU/1/03/262/004 20031113; UK EU/1/03/262/005 20031113; UK EU/1/03/262/006 20031113 |
| 0734381 | PA2004002,C0734381 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: 5-(((2R,3S)-2-((1R)-1-(3,5-BIS(TRIFLUORMETIL)FENIL)ETOKSI)-3-(4-FLUORFENIL)-4-MORFOLINIL)METIL)-1,2-DIHIDRO-3H-1,2,4-TRIAZOL-3-ONAS (APREPITANTAS); REGISTRATION NO/DATE: EU/1/03/262/001, 2003 11 11, EU/1/03/262/002, 2003 11 11, EU/1/03/262/003, 2003 11 11, EU/1/03/262/004, 2003 11 11, EU/1/03/262/005, 2003 11 11, EU/1/03/262/006 20031111 |
| 0734381 | PA2004002 | Lithuania | ⤷ Try a Trial | PRODCUT NAME: 5-[[(2R,3S)-2-[(1R)-1-[3,5-BIS(TRIFLUORMETIL)FENIL]ETOKSI]-3-(4-FLUORFENIL)-4-MORFOLINIL]METIL]-1,2-DIHIDRO-3H-1,2,4-TRIAZOL-3-ONAS (APREPITANTAS); REGISTRATION NO./DATE: EU/1/03/262/001-006/20031111 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
